

# Global, neuronal or $\beta$ cell-specific deletion of inceptor improves glucose homeostasis in male mice with diet-induced obesity

Received: 28 March 2022

Accepted: 19 January 2024

Published online: 28 February 2024

 Check for updates

Gerald Grandl<sup>1,2,9</sup>, Gustav Collden<sup>1,2,9</sup>, Jin Feng<sup>2,3,4,9</sup>, Sreya Bhattacharya<sup>2,3,4,9</sup>, Felix Klingelhuber<sup>1,2</sup>, Leopold Schomann<sup>2,3</sup>, Sara Bilekova<sup>2,3</sup>, Ansarullah<sup>2,3</sup>, Weiwei Xu<sup>2,3</sup>, Fataneh Fathi Far<sup>2,3</sup>, Monica Tost<sup>5</sup>, Tim Gruber<sup>1,2</sup>, Aimée Bastidas-Ponce<sup>2,3</sup>, Qian Zhang<sup>1,2</sup>, Aaron Novikoff<sup>1,2</sup>, Arkadiusz Liskiewicz<sup>1,2</sup>, Daniela Liskiewicz<sup>1,2</sup>, Cristina Garcia-Caceres<sup>1,2,6</sup>, Annette Feuchtinger<sup>5</sup>, Matthias H. Tschöp<sup>2,4,7</sup>, Natalie Krahmer<sup>1,2</sup>, Heiko Lickert<sup>2,3,4</sup>  & Timo D. Müller<sup>1,2,8</sup> 

Insulin resistance is an early complication of diet-induced obesity (DIO)<sup>1</sup>, potentially leading to hyperglycaemia and hyperinsulinaemia, accompanied by adaptive  $\beta$  cell hypertrophy and development of type 2 diabetes<sup>2</sup>. Insulin not only signals via the insulin receptor (INSR), but also promotes  $\beta$  cell survival, growth and function via the insulin-like growth factor 1 receptor (IGF1R)<sup>3–6</sup>. We recently identified the insulin inhibitory receptor (inceptor) as the key mediator of IGF1R and INSR desensitization<sup>7</sup>. But, although  $\beta$  cell-specific loss of inceptor improves  $\beta$  cell function in lean mice<sup>7</sup>, it warrants clarification whether inceptor signal inhibition also improves glycaemia under conditions of obesity. We assessed the glucometabolic effects of targeted inceptor deletion in either the brain or the pancreatic  $\beta$  cells under conditions of DIO in male mice. In the present study, we show that global and neuronal deletion of inceptor, as well as its adult-onset deletion in the  $\beta$  cells, improves glucose homeostasis by enhancing  $\beta$  cell health and function. Moreover, we demonstrate that inceptor-mediated improvement in glucose control does not depend on inceptor function in agouti-related protein-expressing or pro-opiomelanocortin neurons. Our data demonstrate that inceptor inhibition improves glucose homeostasis in mice with DIO, hence corroborating that inceptor is a crucial regulator of INSR and IGF1R signalling.

Insulin resistance (IR) is one of the greatest healthcare challenges of our time<sup>1</sup>. An acute hallmark of IR is  $\beta$  cell hypertrophy, accompanied by progressive hyperinsulinaemia and hyperglycaemia, which may ultimately result in the development of type 2 diabetes (T2D)<sup>2</sup>. IR is often a consequence of prolonged abdominal obesity and is thought to be closely linked to overconsumption of a fat- and carbohydrate-rich

western diet<sup>8</sup>. Understanding the multifaceted aetiology of IR is of utmost importance<sup>9</sup>, because it can cause overt T2D characterized by progressive  $\beta$  cell failure and dependency on insulin replacement therapy<sup>2</sup>. Albeit best known for its glucose-lowering effect, insulin promotes its biological action not only via the INSR, but also via the IGF1R to jointly regulate  $\beta$  cell survival, growth and function<sup>3–6</sup>. Consistent with

A full list of affiliations appears at the end of the paper.  e-mail: [heiko.lickert@helmholtz-munich.de](mailto:heiko.lickert@helmholtz-munich.de); [timodirk.mueller@helmholtz-munich.de](mailto:timodirk.mueller@helmholtz-munich.de)

this, although *Insr* knockout (KO) causes only mild diabetic symptoms with impaired insulin secretory function and total IR in  $\beta$  cells, *Insr/Igf1r* double KO causes overt diabetes associated with reduced  $\beta$  cell mass, increased apoptosis and severely compromised  $\beta$  cell function<sup>10–12</sup>. To ensure adequate islet INSR/IGF1R signalling, insulin-induced receptor activation has to be terminated at some point and the sensitivity of the INSR and IGF1R to get activated by its respective ligand has to be restored. It was only recently that we discovered a key mediator underlying this process in the pancreas, which we named inceptor (encoded by the gene *Iir*)<sup>7</sup>. Consistent with the ability of insulin to signal via INSR and IGF1R, inducible  $\beta$  cell-specific ablation of inceptor increases signalling via both INSR and IGF1R, leading to increased  $\beta$  cell mass and improved glucose tolerance in lean, chow-fed, normoglycaemic mice<sup>7</sup>. But a key open question that remains is whether inceptor inhibition also improves glycaemia under conditions of DIO and glucose intolerance. Besides the pancreas, expression of inceptor is highest in the brain and the pituitary<sup>7</sup>, which further raises the question of whether inceptor also regulates glucose metabolism via central mechanisms. Based on the ability of inceptor to improve islet glucose metabolism via enhanced ligand-induced INSR and IGF1R clathrin-mediated endocytosis and desensitization<sup>7</sup>, modulation of inceptor activity may carry pharmacological potential for the treatment of IR and/or T2D. To corroborate the pharmacological potential of the inceptor–INSR/IGF1R axis, we determined in the present study the spatial and cellular localization of inceptor in the brain, and explored whether whole-body inceptor deficiency, adult-onset  $\beta$  cell-specific loss of inceptor or its targeted Cre-mediated deletion in the central nervous system (CNS), or specifically in pro-opiomelanocortin (POMC) or agouti-related protein (AgRP)-expressing neurons, affects energy and/or glucose metabolism under conditions of DIO in male mice.

To assess whether inceptor inhibition also improves glucose control under conditions of DIO, we generated global inceptor KO mice by crossing *Iir<sup>flx/flx</sup>* mice with mice that express Cre recombinase under the control of the *Rosa26* promoter<sup>13</sup>. Confirming successful target deletion, global inceptor KO mice show largely diminished inceptor immunoreactivity in the brain, pituitary and pancreas relative to wild-type (*Iir<sup>wt/wt</sup>*) (WT) controls (Fig. 1a). When fed with a high-fat diet (HFD), global inceptor KO mice show normal food intake (Fig. 1b), but slightly increased body weight relative to WT controls (Fig. 1c). Impressively, despite showing greater body weight, DIO global inceptor KO mice show improved glucose tolerance relative to WT controls with DIO (Fig. 1d,e), without changes in insulin sensitivity (Fig. 1f,g) or baseline levels of plasma insulin (Fig. 1h). But, consistent with the improved glucose tolerance (Fig. 1d,e), DIO global inceptor KO mice show decreased levels of glycated haemoglobin (HbA1c) (Fig. 1i) and enhanced glucose-stimulated insulin secretion relative to WT controls with DIO (Fig. 1j). Collectively, these data suggest that improved glucose metabolism in global inceptor KO mice originates from enhanced insulin secretion under non-basal conditions, without changes in insulin sensitivity. Consistent with the observation that insulin sensitivity is not changed in the obese inceptor KO mice, we found, after bolus insulin administration, no changes in phosphorylation of the protein kinase AKT in the liver between DIO global inceptor KO mice and their WT controls (Fig. 1k,l). Mass spectrometry (MS)-based proteomic analysis in insulin-sensitive tissues, namely muscle and liver, likewise revealed no overt changes in the proteome signature between DIO global inceptor KO mice and WT controls (Extended Data Fig. 1a–c). No differences are further observed in  $\alpha$  cell or  $\beta$  cell mass (Fig. 1m,n), but plasma levels of glucagon are increased in inceptor KO mice, without changes in fasting levels of blood glucose (Fig. 1o,p).


Based on the predominant expression of inceptor in the CNS, pituitary and pancreas, we next investigated the spatiotemporal expression pattern of inceptor in the CNS more closely. Consistent with previous reports<sup>7</sup>, we found broad inceptor immunoreactivity in the adult mouse brain (Fig. 1a). In the hypothalamus, inceptor immunoreactivity was

high in the arcuate and paraventricular nuclei (ARC and PVN, respectively) and low in the dorsomedial hypothalamic and ventromedial hypothalamic nuclei (DMH and VMH, respectively) (Fig. 2a,b). In the hypothalamus, inceptor immunoreactivity colocalized with the neuronal marker neuronal nuclear protein (*NeuN*, also known as *Fox3*), but not with markers indicative of astrocytes (aldehyde dehydrogenase 1 family member L1, *Aldh1l1*), microglia (glial fibrillary acylated protein, *Cfap*) or neuroglia (ionized calcium-binding adaptor molecule 1, *Iba1*) (Fig. 2c), hence indicating that inceptor was primarily located in CNS neurons. In the hypothalamic ARC, we found inceptor colocalized with neurons that express *Pomc* and neuropeptide Y (*Npy*) (Fig. 2c). It is interesting that hypothalamic inceptor immunoreactivity is increased in the ARC of obese relative to lean mice, with no difference in the PVN, DMH or VMH (Fig. 2d). Hypothalamic inceptor expression further gradually increases during the progression of HFD exposure, and this is paralleled by increased IR, as estimated by homeostatic model assessment for IR (HOMA-IR) (Fig. 2e,f).

Based on the high expression of inceptor in the hypothalamus (Fig. 2a,b) and the well-established role of CNS INSR signalling in the control of systemic glucose homeostasis<sup>14–16</sup>, we next assessed whether targeted neuronal loss of inceptor affects systemic glucose metabolism in mice with DIO. Neuron-specific, inceptor-deficient mice were generated by crossing *Iir<sup>flx/flx</sup>* mice with mice that express Cre recombinase under control of the *Nestin* promoter. Relative to WT controls (*NestinCre<sup>+</sup>Iir<sup>wt/wt</sup>*), neuron-specific inceptor KO mice (*NestinCre<sup>+</sup>Iir<sup>flx/flx</sup>*) show largely blunted inceptor immunoreactivity in the brain, including the hypothalamus (Fig. 3a). When chronically fed an HFD, Nestin Cre inceptor KO mice showed no difference in body weight (Fig. 3b), food intake (Fig. 3c) or fat mass (Fig. 3d) relative to WT controls, but slightly elevated lean tissue mass (Fig. 3e). No differences were observed in fasting levels of blood glucose (Fig. 3f), but, similar to whole-body inceptor KO mice, glucose tolerance was increased in obese Nestin Cre inceptor KO mice relative to WT controls (Fig. 3g,h). Similar to mice with global inceptor deficiency, neuronal loss of inceptor did not lead to changes in insulin sensitivity (Fig. 3i,j). MS-based analysis in muscle, liver and hypothalamus showed, likewise, no overt changes in the proteome signature between Nestin Cre inceptor KO mice and their WT controls (Extended Data Fig. 2a–c). No differences were further observed in baseline levels of plasma insulin or glucagon (Fig. 3k,l) or in  $\alpha$  cell and  $\beta$  cell mass (Fig. 3m,n).


As a result of the demonstrated colocalization of inceptor with POMC and AgRP (Fig. 2c), both of which are implicated in regulating systemic energy metabolism<sup>17</sup>, we next assessed whether deletion of inceptor specifically in these neurons affects whole-body energy and glucose metabolism. Mice with deletion of inceptor in either AgRP or POMC neurons were generated by crossing *Iir<sup>flx/flx</sup>* mice with mice that express Cre recombinase under control of either the *Agrp* or *Pomc* promoter<sup>18,19</sup>. Compared with *Agrp-Cre<sup>+/+</sup>Iir<sup>wt/wt</sup>* (WT) controls, HFD-fed mice with *Agrp*-specific loss of inceptor (*Agrp-Cre<sup>+/+</sup>Iir<sup>flx/flx</sup>*) show reduced inceptor immunoreactivity in the ARC (Extended Data Fig. 3a), but without difference in body weight or body composition relative to WT controls (Extended Data Fig. 3b–d). *Agrp*-specific inceptor KO mice show slightly elevated levels of fasting blood glucose (Extended Data Fig. 3e), without differences in glucose tolerance or insulin sensitivity relative to WT controls (Extended Data Fig. 3f–i).

Deletion of inceptor in POMC neurons was verified using immunohistochemistry (IHC) by demonstrating that inceptor colocalizes with POMC in WT but not POMC inceptor KO mice (Extended Data Fig. 3j). When fed with an HFD, POMC inceptor KO mice show no differences in body weight, body composition or blood glucose relative to WT controls (Extended Data Fig. 3k–n). No changes are further observed in glucose tolerance or insulin sensitivity (Extended Data Fig. 3o–r). Collectively, these data indicate that the improved glucose metabolism that is observed in the global and neuronal inceptor KO



**Fig. 1 | Whole-body inceptor deletion improves glucose metabolism in male mice with DIO. a**, Inceptor immunoreactivity in whole brain, pituitary and pancreas of 10-week-old male C57BL/6J inceptor *lir<sup>+/+</sup>* (WT) and *lir<sup>-/-</sup>* (KO) mice. Scale bars, 1 mm for brain, 200  $\mu$ m for pituitary and 20  $\mu$ m for pancreas. **b,c**, Food intake (**b**) in 28-week-old and body weight (**c**) in 10- to 30-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). **d,e**, Intraperitoneal glucose tolerance (**d**) and area under the curve (AUC) (**e**) in 19-week-old male C57BL/6J WT and KO mice ( $n = 7$  WT,  $n = 8$  KO). **f,g**, Intraperitoneal insulin tolerance (**f**) and AUC (**g**) in 23-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). **h,i**, Fasting levels of plasma insulin ( $n = 8$  for each genotype) (**h**) and levels of HbA1c in 27-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype) (**i**). **j**, Glucose-stimulated insulin secretion in 27-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). **k,l**, Western blots of liver protein of 30-week-old

male C57BL/6J WT and KO mice treated with a single dose of saline or 1 mU per kg of insulin ( $n = 4$  for each group) (**k**) and densitometric quantification (**l**). **m,n**, Pancreatic  $\alpha$  cell (**m**) and  $\beta$  cell (**n**) mass in 30-week-old male C57BL/6J WT and KO mice ( $n = 5$  for each genotype). **o,p**, Fasting plasma levels of glucagon (**o**) and blood glucose (**p**) in 19-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . Data are presented as mean  $\pm$  s.e.m. Data in **b**, **e**, **g-i** and **l-p** were analysed by two-sided, two-tailed Student's *t*-test. Data in **c**, **d**, **f** and **j** were analysed by two-way ANOVA with Bonferroni's post hoc, multiple-comparison test for the different time points. *P* values for group differences are:  $P = 0.0049$  (**c**),  $P = 0.0082$  (**d**),  $P = 0.010$  (**e**),  $P = 0.0098$  (**i**),  $P = 0.0021$  (**j**),  $P = 0.002$  (WT) and  $P = 0.0016$  (KO) (**l**) and  $P = 0.0232$  (**o**). *P* values for the multiple-comparison tests are provided in Source data. Corr., corrected; vhc1, vehicle.




**Fig. 2 | Central inceptor immunoreactivity is restricted to neurons, including those regulating energy and glucose metabolism.** **a**, **b**, Representative image (**a**) and quantification (**b**) of inceptor immunoreactivity in hypothalamic nuclei of 18- to 24-week-old male C57BL/6J WT mice ( $n = 30$  mice for ARC and DMH,  $n = 28$  mice for VMH,  $n = 19$  mice for PVN). Scale bar, 200  $\mu$ m. **c**, Inceptor colocalization with *NeuN*, *Pomc*-green fluorescent protein (GFP), *Npy*-GFP, *Aldhl1*-GFP, *Gfap* and *Iba1* in the hypothalamus of 28-week-old male C57BL/6J WT mice. Scale bars, 50  $\mu$ m. **d**, Inceptor immunoreactivity in 28-week-old chow- versus HFD-fed male C57BL/6J WT mice ( $n = 5$  for all regions except PVN;  $n = 3$ ). **e**, Hypothalamic inceptor messenger RNA expression in 10-week-old male

C57BL/6J WT mice fed with either chow or HFD ( $n = 4$  per group). **f**, HOMA-IR in 14-week-old C57BL/6J WT mice fed with either chow or HFD ( $n = 8$ ). \* $P < 0.05$ . Data are presented as mean  $\pm$  s.e.m. Data in **b** and **e** were analysed by one-way ANOVA, data in **d** were analysed by two-way ANOVA and data in **f** were analysed using the Kruskal-Wallis test.  $P$  values for group differences are:  $P < 0.0001$  (ARC versus VMH),  $P < 0.0001$  (ARC versus DMH),  $P = 0.0046$  (ARC versus PVN),  $P = 0.0014$  (VMH versus DMH),  $P < 0.0001$  (VMH versus PVN),  $P < 0.0001$  (DMH versus PVN) (**b**),  $P = 0.0156$  (**d**),  $P = 0.0137$  (**e**),  $P = 0.0217$  (chow versus HFD 14 d) and  $P = 0.0232$  (chow versus HFD 28 d) (**f**). A more detailed statistical report is provided in Source data. Rel., relative.

mice is not mediated by impaired inceptor function in either POMC or AgRP neurons.

Based on the demonstrated role of inceptor to regulate islet glucose metabolism in lean mice<sup>7</sup>, we next assessed whether targeted deletion of inceptor in adult pancreatic  $\beta$  cells improves glycaemic control also under conditions of DIO. Adult-onset,  $\beta$  cell, inceptor-deficient mice were generated by crossing *Iir<sup>flx/flx</sup>* mice to mice that express Cre recombinase in a tamoxifen-inducible manner under control of the *Ins1* promoter. Tamoxifen induction of  $\beta$  cell

inceptor KO was initiated at the age of 26 weeks and was verified by IHC (Fig. 4a). When chronically fed with an HFD, adult-onset  $\beta$  cell inceptor KO mice (*Ins1Cre<sup>ERT+/+</sup>-Iir<sup>flx/flx</sup>*) show no differences in body weight (Fig. 4b), body composition (Fig. 4c,d) or blood glucose (Fig. 4e) relative to WT controls (*Ins1Cre<sup>ERT+/+</sup>-Iir<sup>flx/flx</sup>*), but display improved glucose tolerance (Fig. 4f,g) and enhanced insulin sensitivity (Fig. 4h,i). Furthermore, mice with adult-onset  $\beta$  cell inceptor deletion show no significant difference in fasted plasma levels of insulin (Fig. 4j) and no changes in plasma glucagon or  $\alpha$  cell mass (Fig. 4k,l), but slightly




**Fig. 3 | Neuronal loss of inceptor improves glucose metabolism without affecting body weight in male mice with DIO.** **a**, Inceptor immunoreactivity in the hypothalamus of 11-week-old male C57BL/6J *Nestin Cre<sup>+/+</sup> Ir<sup>wt/wt</sup>* (WT) and *Nestin Cre<sup>+/+</sup> Ir<sup>flx/flx</sup>* (KO) mice. Scale bars, 200  $\mu\text{m}$ . **b–f**, Body weight (**b**), cumulative food intake (**c**), as well as fat mass (**d**) and lean tissue mass (**e**) and fasting plasma levels of blood glucose (**f**), in 26-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype) on an HFD. **g,h**, Intraperitoneal glucose tolerance (**g**) and AUC (**h**) in 27-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). **i,j**, Intraperitoneal insulin tolerance (**i**) and AUC (**j**) in 28-week-old male C57BL/6J mice on an HFD ( $n = 6$  WT,  $n = 5$  KO). **k,l**, Fasting levels of insulin in 27-week-old and 32-week-old C57BL/6J WT and KO mice ( $n = 8$  for each group)

(**k**) and fasting levels of glucagon in 27-week-old and 32-week-old C57BL/6J WT ( $n = 6$ ) and KO mice ( $n = 5$ ) (**l**). **m,n**, Pancreatic  $\alpha$  cell (**m**) and  $\beta$  cell (**n**) mass in 36-week-old C57BL/6J WT and KO mice ( $n = 6$  WT,  $n = 5$  KO). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . Data are presented as mean  $\pm$  s.e.m. Data in **d, e, h, j, k, l, m** and **n** were analysed by two-sided, two-tailed Student's *t*-test, data in **f** were analysed using the Mann–Whitney *U*-test and data in **b, c, g** and **i** were analysed by two-way ANOVA with Bonferroni's post hoc comparison for individual time points. *P* values for group differences are  $P < 0.0169$  (**e**),  $P = 0.0123$  (**g**) and  $P = 0.0074$  (**h**). A more detailed statistical report and the *P* values for the multiple-comparison test (**g**) are provided in Source data.

increased  $\beta$  cell mass (Fig. 4m), and a significant improvement in HbA1c levels (Fig. 4n). No overt changes were observed on the proteome of either the liver or the muscle (Extended Data Fig. 4a–c).

In summary, our data show that mice with DIO and perturbed inceptor function in either the whole body or specifically in CNS neurons or the pancreatic  $\beta$  cells are protected from diet-induced

glucose intolerance. Preservation of glucose tolerance in obese global inceptor-deficient mice is not related to changes in body weight, food intake or insulin sensitivity, but is associated with enhanced glucose-stimulated insulin secretion. Furthermore, it was shown that inceptor immunoreactivity is high in hypothalamic areas regulating energy and glucose metabolism and that inceptor colocalizes with



**Fig. 4 | DIO male mice with adult-onset,  $\beta$  cell-specific inceptor deletion show improved glucose metabolism.** **a**, Inceptor immunoreactivity in the pancreas of male 26-week-old *Ins1Cre<sup>ERT2</sup>-/-;Iir<sup>flx/flx</sup>* (WT) and *Ins1Cre<sup>ERT2</sup>-/-;Iir<sup>flx/flx</sup>* (KO) C57BL/6J mice. Scale bars, 20  $\mu$ m. **b–e**, Body weight (**b**), as well as lean (**c**) and fat (**d**) tissue mass and fasting glucose (**e**) in 30-week-old male C57BL/6J WT and KO mice ( $n = 8$  for each genotype). Tam, Tamoxifen. **f, g**, Intraperitoneal glucose tolerance (**f**) and AUC (**g**) in 18-week-old male C57BL/6J WT and KO mice on an HFD ( $n = 8$  for each genotype). **h, i**, Intraperitoneal insulin tolerance (**h**) and AUC (**i**) in 18-week-old male C57BL/6J WT and KO mice on an HFD ( $n = 10$  for each genotype). **j, k**, Fasting levels of plasma insulin (**j**) and glucagon (**k**) ( $n = 10$  for each genotype) in 22-week-old male C57BL/6J WT

and KO mice. **l, m**, Pancreatic  $\alpha$  cell mass (**l**;  $n = 5$  each genotype) and  $\beta$  cell mass (**m**;  $n = 6$  WT,  $n = 5$  KO) in 26-week-old male C57BL/6J WT and KO mice. **n**, Whole-blood HbA1c in 18-week-old male C57BL/6J WT and KO mice ( $n = 10$  mice per genotype). \* $P < 0.05$ , \*\* $P < 0.01$ . Data are presented as mean  $\pm$  s.e.m. Data in **c, d, e, g, i, j, k, l, m** and **n** were analysed by two-sided, two-tailed Student's  $t$ -test, data in **b, f** and **h** were analysed by two-way ANOVA with Bonferroni's post hoc comparison for individual time points and data in **n** were analysed using Mann–Whitney  $U$ -test.  $P$  values for group differences are  $P < 0.0426$  (**f**),  $P = 0.0322$  (**g**),  $P = 0.0382$  (**h**),  $P = 0.0379$  (**i**),  $P = 0.0142$  (**m**) and  $P = 0.002$  (**n**). A more detailed statistical report and the  $P$  value for the multiple-comparison test (**f**) are provided in Source data.

neuronal markers (including POMC and AgRP), but not with markers indicative of astrocytes, neuroglia or microglia. In striking contrast to mice with neuronal loss of inceptor, we have shown that targeted deletion of inceptor in either POMC or AgRP neurons does not protect mice with DIO from glucose intolerance. Collectively, our data show that, under conditions of DIO, inceptor functions in both the CNS and

pancreatic  $\beta$  cells regulate whole-body glucose metabolism, without major effects on body weight or body composition. Furthermore, we identified CNS neurons as the primary source of inceptor expression in the brain, and exclude a role of inceptor function in POMC or AgRP neurons in the regulation of glucose metabolism. Our data are consistent with our previous report showing that inceptor plays a key role

in regulating islet insulin action in lean normoglycaemic mice<sup>7</sup> and supports the hypothesis that inhibition of inceptor to sensitize INSR/IGF1R action may be a promising pharmacological target in the context of diet-induced impairments of glucose homeostasis, in particular with regard to  $\beta$  cell mass and health, with the potential to avoid  $\beta$  cell failure and slow diabetes progression. Notably, similar to the whole-body inceptor KO, we show that pan-neuronal loss of inceptor improves glucose metabolism in mice with DIO without affecting body weight or body composition, suggesting that central loss of inceptor does not fully restore central insulin sensitivity under conditions of DIO, but acts on glucose homeostasis by a different mechanism<sup>14,17,20</sup>. The observation that CNS loss of inceptor improves systemic glucose tolerance in mice with DIO is consistent with previous reports that link central insulin action to control of peripheral glucose metabolism<sup>20,21</sup>, as well as a recently published paper, showing that inceptor is co-expressed with INSR and IGF1R in neurons and that knockdown of inceptor increases insulin sensitivity in ex vivo neuron cultures<sup>22</sup>. However, we show that these central effects are not mediated via inceptor action in AgRP or POMC neurons. Nevertheless, underlining the potential relevance of inceptor inhibition for the treatment of diabetes, we have shown in the present study that targeted adult-onset loss of inceptor in pancreatic  $\beta$  cells renders mice with DIO less susceptible to diet-induced impairment of glucose metabolism, primarily by improving  $\beta$  cell health and function. These data are consistent with reports indicating the necessity of early interventions to maintain adequate  $\beta$  cell glucose sensitivity<sup>21</sup>. In line with this notion, early intensive insulin therapy has been demonstrated to recover and maintain  $\beta$  cell maintenance and function, and to slow down progression of T2D<sup>23</sup>, but with the potential side effects of inducing hypoglycaemia and body weight gain<sup>24–28</sup>. The beneficial effects of early insulin are thought to be primarily through reduced glucotoxicity, which undermines  $\beta$  cell function. We have recently shown, in streptozotocin-induced diabetic mice, that long-term hyperglycaemia and  $\beta$  cell dysfunction/dedifferentiation can be counteracted by intense prolonged insulin therapy<sup>6</sup>. It is interesting that single-cell RNA sequencing data of islet cells revealed that INSR signalling by exogenous insulin supplementation triggered  $\beta$  cell redifferentiation and regeneration for diabetes remission, again confirming that increased insulin action has direct beneficial effects on  $\beta$  cell health and function<sup>6</sup>. Hence, in contrast to intense, early onset insulin therapy, inceptor-mediated improvement of  $\beta$  cell function may offer the potential to counteract the detrimental glucometabolic effects of DIO without the risk of causing hypoglycaemia or unwanted body weight gain.

## Methods

### Animals and housing conditions

Animal experiments were performed in accordance with the Animal Protection Law of the European Union and with the permission of the government of upper Bavaria (Regierung von Oberbayern), Germany. Only male mice were used in the studies, because female mice are largely resistant to DIO and alterations in glucose metabolism when chronically fed with an HFD<sup>29</sup>. Mice were fed a 58% high-fat, high-sucrose diet (Research Diets, catalogue no. D12331) and were group housed on a 12:12 h light:dark cycle at  $22 \pm 1$  °C, 45–55% humidity and with free access to food and water unless indicated otherwise. C57BL/6J mice were provided by Janvier Labs. Transgenic mice were generated on a C57BL/6J background as described. *Nestin-Cre* mice (catalogue no. 003771)<sup>30</sup>, *Ins1-Cre<sup>ERT</sup>* mice (MGI: catalogue no. 4410453)<sup>31</sup>, *AgRP-Cre* mice (catalogue no. 012899)<sup>19</sup> and *Pomc-Cre* mice (catalogue no. 005965)<sup>18</sup> were purchased from the Jackson Laboratories.

### Animal metabolic studies

Food consumption was measured per cage in double-housed, or temporally single-housed, mice. Body composition (fat and lean mass) was measured using quantitative nuclear magnetic resonance technology

(EchoMRI). For analysis of glucose tolerance or insulin tolerance, mice were fasted for 6 h, followed by intraperitoneal administration of 1.5–2 g kg<sup>-1</sup> of glucose or 0.5–1 U kg<sup>-1</sup> of insulin (Humalog, Eli Lilly). Plasma levels of insulin and glucagon were measured by ELISA (Crystal Chem, catalogue nos. 90082, 8151890050) following the manufacturer's instructions.

### IHC

For brain images, mice were perfused with phosphate-buffered saline followed by 4% paraformaldehyde (Thermo Fisher Scientific), post-fixed for 1 d, equilibrated in 30% sucrose for 1 d and sectioned on a cryostat (Leica Biosystems) at 30–40  $\mu$ m. Staining was performed in 0.1 M tris-buffered solution with 0.25% gelatine (0.25%) and 0.5% Triton X-100. For the pancreas, dissected pancreatic cryo-samples were cryosectioned at 12  $\mu$ m and briefly fixed in formalin (formalin 10% neutral buffered, Sigma-Aldrich, catalogue no. HT501128). Pancreatic islets were analysed by triple staining for insulin, glucagon and inceptor. A complete list of primary and secondary antibodies and dilutions is provided in Supplementary Information. Nuclei were identified with Hoechst 33342. Stained slides were digitized with an AxioScan 7 digital slide scanner (Zeiss, ZEN Blue v.3.5) equipped with a  $\times 20$  magnification objective.

### IHC for $\alpha$ cell and $\beta$ cell volume and islet size

Dissected pancreata were fixed in formalin (formalin 10% neutral buffered) for 24 h at room temperature and processed for paraffin embedding (Tissue Tec VIP.6, Sakura Europe). Paraffinized pancreata were cross-sectioned into three to four parallel, equidistant slices per case. Maintaining their orientation, the tissue slices were vertically embedded in paraffin. After costaining for insulin and glucagon, nuclei were labelled with Hoechst 33342 (Thermo Fisher Scientific, catalogue no. H13997, 5  $\mu$ g ml<sup>-1</sup>). A complete list of primary and secondary antibodies and dilutions is provided in Supplementary Information. The stained tissue sections were scanned with an AxioScan 7 digital slide scanner (Zeiss, ZEN Blue v.3.5) equipped with a  $\times 20$  magnification objective. Quantification of insulin or glucagon expression cells was performed on the entire tissue sections by using image analysis software Visiopharm. The insulin- or glucagon-expressing cells were classified automatically using the fluorescence intensity of each hormone. The  $\beta$  cell volume (mg) was calculated by multiplying the detected relative insulin-positive cell area by total pancreatic weight. The  $\alpha$  cell volume (mg) was similarly calculated based on the detected glucagon-positive cell area. The area of the pancreatic islet was calculated based on the insulin- and glucagon-positive area.

### Proteomics sample preparation

Tissues were disrupted using a tissuelyser (QIAGEN), heated for 5 min at 95 °C and 1,000 r.p.m. in 2% sodium deoxycholate (SDC) buffer (2% SDC, 100 mM Tris-HCl, pH 8.5) and sonicated (Diagenode Bioruptor, 15  $\times$  30 s at high intensity); for liver and muscle, each step was done twice. After centrifugation, the protein concentration of the supernatant was determined using the BCA Protein Assay (Thermo Fisher Scientific, catalogue no. 23225). Protein, 25  $\mu$ g per sample, was reduced, alkylated with 10 mM tris(2-carboxyethyl)phosphine and 40 mM chloroacetamide at 40 °C in the dark for 10 min and then digested overnight (37 °C, 1,000 r.p.m.) with a 1:50 ratio (protein:enzyme) of trypsin (Sigma-Aldrich, catalogue no. t6567) and LysC (Wako, catalogue no. 129-02541). On the next day, peptides were acidified and loaded on to activated triple layer styrene divinylbenzene-reversed-phase-sulfonated STAGE tips (SDB-RPS; 3M Empore). Peptides were washed with 100  $\mu$ l of ethylacetate, 1% trifluoroacetic acid (TFA), 100  $\mu$ l of 30% methanol, 1% TFA and 150  $\mu$ l of 0.2% TFA and eluted with 60  $\mu$ l of elution buffer (80% acetonitrile (ACN), 5% NH<sub>4</sub>OH). Peptides were lyophilized and dissolved in 10  $\mu$ l of MS-loading buffer (2% ACN, 0.1% TFA).

### LC-MS/MS analysis

Liquid chromatography–tandem MS (LC-MS/MS) analysis of 500 ng of peptides was performed on an Orbitrap Exploris 480 (Thermo Fisher Scientific) equipped with a nano-electrospray ion source and FAIMS (CV50), coupled to an EASY-nLC 1200 high-performance LC (HPLC) (all Thermo Fisher Scientific). The LC was equipped with a 50-cm column packed in-house with ReproSil-Pur C18-AQ1.9- $\mu\text{m}$  resin (Dr. Maisch HPLC GmbH). The peptides were separated at 60 °C over 1 h by reversed-phase chromatography using a binary buffer system consisting of buffer A (0.1 formic acid) and buffer B (80% ACN, 0.1% formic acid). Starting with 5% buffer B, this fraction was increased stepwise to 45% over 45 min, followed by a wash-out at 95%, all at a constant flow rate of 300 nl min<sup>-1</sup>. After using electrospray ionization to transfer the peptides to the mass spectrometer, a data-independent method was used for measurement. For this, one ms1 scan (300–1,650  $m/z$ , maximum ion fill time of 45 ms, normalized automatic gain control (AGC) target = 300%,  $R = 120.000$  at 200  $m/z$ ) was followed by 66-ms<sup>2</sup> fragment scans of unequally spaced windows (fill time = 22 ms, normalized AGC target = 1,000%, normalized higher-energy collision dissociation collision energy = 30%,  $R = 15.000$ )

### Data analysis for proteomics

DIA raw files were demultiplexed with Spectronaut HTRMS converter and analysed with Spectronaut (v.18.1.230626.50606). Analysis of the resulting protein file was performed in Perseus (v.1.6.15.0) using standard parameters if not stated otherwise. Proteomic samples that showed a considerably lower protein group count than others in the same tissue were excluded. The log<sub>2</sub>(transformed) values with <4 s.d. of the average distribution were considered missing values. Thereafter protein groups were filtered for a minimum of three values in at least one sample group (tissue + genotype) and missing values imputed with a normal distribution (downshift 1.8 stdvs, width 0.3).

### Western blotting

Protein samples were prepared as described for proteomics. Protein, 20  $\mu\text{g}$ , was run on a sodium dodecylsulfate–polyacrylamide gel electrophoresis gradient gel (4–20%) in a Protean System (BioRad) in 25 mM Tris, 192 mM glycine, pH 8.3 buffer. Samples were transferred to poly(vinylidene fluoride) membranes using a BioRad Turboblot system, stained with primary anti-Akt (Cell Signaling, catalogue no. 2920, 1:1,000) and p-AKT S473 (Cell Signaling, catalogue no. 4060, 1:1,000) antibodies, and secondary antibodies (BioRad, Starbright 700, anti-rabbit Alexa Fluor-790 anti-mouse (Abcam, catalogue no. ab175781), both 1:6,000) and detected on a BioRad ChemiDoc system with a fluorescence detection module.

### Image analysis

Images were obtained as serial z-stacks using a Leica SP5 or LSM 880 Airyscan microscope (Zeiss, ZEN Black v.2.3) as tile scans (10% overlap). Final images were analysed and processed with ImageJ (v.2.14; Java 1.8). Inceptor colocalization was performed with manual blind counting. The mean fluorescence intensity in hypothalamic target regions was measured on unaltered images and corrected for background fluorescence using Fiji 1.0 (ImageJ). When possible, quantifications were performed on several sections spanning the medial ARC nucleus and PVN and averaged.

### Gene expression analysis

RNA was extracted using RNeasy Mini Kits (QIAGEN). Complementary DNA was generated with QuantiTech reverse transcription kit (QIAGEN). Quantitative PCR was performed with a ViiA 7 PCR System (Applied Biosystems) using the TaqMan probes *Hprt* (Mm01545399\_m1) and *inceptor* (Mm00478295\_m1) from Thermo Fisher Scientific. Target gene expression was normalized to reference gene *Hprt*, by  $\Delta\Delta C^T$ .

### Statistics

For animal studies, sample sizes were calculated based on a power analysis assuming that a  $\geq 5$ -g difference in body weight between genotypes can be assessed with a power of  $\geq 75\%$  when using a two-sided statistical test under the assumption of an s.d. of 3.5 and an  $\alpha$  level of 0.05. Statistical analyses were performed two sided, using the statistical tools implemented in GraphPad Prism. Before statistical analysis, data were tested for normal distribution using the Kolmogorov–Smirnow test with Lillifors correction. In the case of non-normal distribution, data were analysed using either the Mann–Whitney *U*-test or the Kruskal–Wallace test. In the case of normal distribution, data were analysed using an unpaired (two-sided), two-tailed Student's *t*-test, one-way analysis of variance (ANOVA) or two-way ANOVA, followed by an appropriate post hoc multiple-comparison test as indicated in the figure legends.  $P \leq 0.05$  was considered statistically significant. Animals were either randomly assigned into treatment groups or grouped based on their genotype (WT or KO). At the study's start, only age-matched mice were included in the studies. No other covariates were controlled for. Analyses of glucose and insulin tolerance were performed by experienced research assistants who did not know prior treatment conditions. Ex vivo studies were performed in ID-coded vials without statement of treatment on the vials and with most, but not all, investigators being blinded to the underlying genotypes and treatment conditions. No data were excluded from the analysis unless scientific (for example, outlier identified by the Grubbs test for outlier) or animal welfare reasons (for example, injury due to fighting) demanded exclusion. Outliers are stated in Source data.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

The data used for the statistical analysis are available in Source data, along with the GraphPad Prism-derived report on the statistical analysis as appropriate. The statistical report contains the mean difference between the treatment groups, the 95% confidence intervals, the significance summary and the exact *P* values (unless  $P < 0.0001$ ). The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE<sup>32</sup> partner repository with the accession no. [PXD046256](https://doi.org/10.26434/chemrxiv-2024-pxd04). Raw images are included in Source data, with the exception of the histology pictures in Figs. 1m,n, 3m,n and 4l,m, which were too large for public repositories and are available from the corresponding authors upon request. Source data are provided with this paper.

### Code availability

No customized code was used for the present study.

### References

1. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* **387**, 1513–1530 (2016).
2. Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. *Lancet* **389**, 2239–2251 (2017).
3. Goldfine, A. B. & Kulkarni, R. N. Modulation of  $\beta$ -cell function: a translational journey from the bench to the bedside. *Diabetes Obes. Metab.* **14**, 152–160 (2012).
4. Leibiger, I. B., Leibiger, B. & Berggren, P.-O. Insulin signaling in the pancreatic beta-cell. *Annu. Rev. Nutr.* **28**, 233–251 (2008).
5. Rhodes, C. J., White, M. F., Leahy, J. L. & Kahn, S. E. Direct autocrine action of insulin on  $\beta$ -cells: does it make physiological sense? *Diabetes* **62**, 2157–2163 (2013).
6. Sachs, S. et al. Targeted pharmacological therapy restores  $\beta$ -cell function for diabetes remission. *Nat. Metab.* **2**, 192–209 (2020).



7. Ansarullah et al. Inceptor counteracts insulin signalling in beta-cells to control glycaemia. *Nature* **590**, 326–331 (2021).
8. Lingvay, I., Sumithran, P., Cohen, R. V. & le Roux, C. W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet* **399**, 394–405 (2022).
9. Grandl, G. et al. Short-term feeding of a ketogenic diet induces more severe hepatic insulin resistance than an obesogenic high-fat diet. *J. Physiol.* **596**, 4597–4609 (2018).
10. Kulkarni, R. N. et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell* **96**, 329–339 (1999).
11. Skovsø, S. et al. Beta-cell specific *Insr* deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance. *Nat. Commun.* **13**, 735 (2022).
12. Ueki, K. et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. *Nat. Genet.* **38**, 583–588 (2006).
13. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**, 70–71 (1999).
14. Könnner, A. C. & Brüning, J. C. Selective insulin and leptin resistance in metabolic disorders. *Cell Metab.* **16**, 144–152 (2012).
15. Mirzadeh, Z., Faber, C. L. & Schwartz, M. W. Central nervous system control of glucose homeostasis: a therapeutic target for type 2 diabetes? *Annu. Rev. Pharmacol. Toxicol.* **62**, 55–84 (2022).
16. Plum, L., Belgardt, B. F. & Brüning, J. C. Central insulin action in energy and glucose homeostasis. *J. Clin. Invest.* **116**, 1761–1766 (2006).
17. Kullmann, S. et al. Central nervous pathways of insulin action in the control of metabolism and food intake. *Lancet Diabetes Endocrinol.* **8**, 524–534 (2020).
18. Balthasar, N. et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. *Neuron* **42**, 983–991 (2004).
19. Tong, Q., Ye, C.-P., Jones, J. E., Elmquist, J. K. & Lowell, B. B. Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. *Nat. Neurosci.* **11**, 998–1000 (2008).
20. Ruud, J., Steculorum, S. M. & Brüning, J. C. Neuronal control of peripheral insulin sensitivity and glucose metabolism. *Nat. Commun.* **8**, 15259 (2017).
21. Heni, M., Kullmann, S., Preissl, H., Fritsche, A. & Häring, H. U. Impaired insulin action in the human brain: causes and metabolic consequences. *Nat. Rev. Endocrinol.* **11**, 701–711 (2015).
22. Post, L. A. et al. Inceptor as a regulator of brain insulin sensitivity. *Sci. Rep.* **13**, 11582 (2023).
23. Hanefeld, M., Fleischmann, H., Siegmund, T. & Seufert, J. Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update. *Diabetes Ther.* **11**, 1645–1666 (2020).
24. Chiasson, J.-L. Early insulin use in type 2 diabetes: what are the cons? *Diabetes Care* **32**, S270–S274 (2009).
25. Li, Y. et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. *Diabetes Care* **27**, 2597–2602 (2004).
26. Meneghini, L. F. Early insulin treatment in type 2 diabetes: what are the pros? *Diabetes Care* **32**, S266–S269 (2009).
27. Raz, I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. *Diabetes Care* **36**, S139–S144 (2013).
28. Ryan, E. A., Imes, S. & Wallace, C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. *Diabetes Care* **27**, 1028–1032 (2004).
29. Pettersson, U. S., Walden, T. B., Carlsson, P.-O., Jansson, L. & Phillipson, M. Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. *PLoS ONE* **7**, e46057 (2012).
30. Tronche, F. et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. *Nat. Genet.* **23**, 99–103 (1999).
31. Wicksteed, B. et al. Conditional gene targeting in mouse pancreatic  $\beta$ -cells: analysis of ectopic Cre transgene expression in the brain. *Diabetes* **59**, 3090–3098 (2010).
32. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2022).

## Acknowledgements

We thank L. Sehner, E. Malogajski, M. Killian, X. Leonhardt, P. Dörfelt, L. Fetzer, W. Liu and S. Ribicic from the Institute for Diabetes and Obesity at Helmholtz Munich, and C. Eggert from the Institute of Diabetes and Regeneration Research at Helmholtz Munich for their skilful technical assistance. T.D.M. received funding for this work from the European Research Council ERC-CoG trusted no.101044445. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the ERC. Neither the European Union nor the awarding authority can be held responsible for them. T.D.M. received further funding from the German Research Foundation (DFG, grant nos. TRR296, TRR152, SFB1123 and GRK 2816/1) and the German Center for Diabetes Research (DZD e.V.). H.L. acknowledges support by Helmholtz Munich, the Helmholtz Association, the DZD and the European Union (ERC, BetaRegeneration-101054564). M.H.T. received funding from the Alexander von Humboldt Foundation, the Helmholtz Alliance ICeMED and the Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association, the Helmholtz cross-programme topic Metabolic Dysfunction and the ERC AdG *HypoFlam* no. 695054. C.G.-C. received funding from the DZD, the ERC (CGC: STG grant AstroNeuroCrosstalk no. 757393), the DFG under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198) and the Helmholtz Association—Initiative and Networking Fund.

## Author contributions

G.G., G.C., S. Bhattacharya and J.F. designed and performed experiments, and analysed and interpreted data. F.K., L.S., S. Bilekova, M.T., A.L., D.L., A., W.X., F.F.F., T.G., A.B.-P., Q.Z. and A.N. performed experiments and analysed data. A.F., C.G.-C., N.K. and M.H.T. participated in study design, supervision of experiments and interpretation of data. T.D.M. and H.L. conceptualized the project, supervised experiments and analysed and interpreted data. G.G., T.D.M. and H.L. wrote the paper with support from G.C., S. Bhattacharya and J.F.

## Funding

Open access funding provided by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).

## Competing interests

M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, MA. He was a member of the Research Cluster Advisory Panel of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016), and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018) and, since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies

and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to, pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, ArboMed, BioSyngen and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München such as WO/2016/188932 A2 or WO/2017/194499 A1. M.H.T. confirms that, to the best of his knowledge, none of the above funding sources was involved in the preparation of the present paper. T.D.M. receives research funding from Novo Nordisk and has received speaking fees from Eli Lilly, AstraZeneca, Novo Nordisk and Merck. H.L. is cofounder of the Viacure GmbH and has ownership interest. H.L. is the inventor of the patent 'Novel IGFR-like receptor and uses thereof' held by the Helmholtz Zentrum München GmbH (WO2017042242) and co-inventor of the pending patent application filed by the Helmholtz Zentrum München GmbH 'Novel IGFR-like 1 monoclonal antibodies and uses thereof' (WO2023002060). The other authors declare no competing interests.

### Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s42255-024-00991-3>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42255-024-00991-3>.

**Correspondence and requests for materials** should be addressed to Heiko Lickert or Timo D. Müller.

**Peer review information** *Nature Metabolism* thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Yanina-Yasmin Pesch, in collaboration with the *Nature Metabolism* team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024


<sup>1</sup>Institute of Diabetes and Obesity, Helmholtz Center Munich, Neuherberg, Germany. <sup>2</sup>German Center for Diabetes Research, Neuherberg, Germany. <sup>3</sup>Institute of Diabetes and Regeneration Research, Helmholtz Center Munich, Neuherberg, Germany. <sup>4</sup>School of Medicine, Technische Universität München, Munich, Germany. <sup>5</sup>Core Facility Pathology & Tissue Analytics, Helmholtz Center Munich, Munich, Germany. <sup>6</sup>Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>7</sup>Helmholtz Zentrum München, Neuherberg, Germany. <sup>8</sup>Walther-Straub Institute of Pharmacology and Toxicology, LMU Munich, Munich, Germany. <sup>9</sup>These authors contributed equally: Gerald Grandl, Gustav Collden, Jin Feng, Sreya Bhattacharya. ✉e-mail: [heiko.lickert@helmholtz-munich.de](mailto:heiko.lickert@helmholtz-munich.de); [timodirk.mueller@helmholtz-munich.de](mailto:timodirk.mueller@helmholtz-munich.de)



Extended Data Fig. 1 | See next page for caption.

**Extended Data Fig. 1 | Proteome analysis of liver and muscle of whole body inceptor KO vs. WT mice.** Principle component analysis (PCA) of all tissue samples (a). Clustering of quadriceps muscle (left), liver (middle) and hypothalamus (right) samples as well as z-scored protein intensities. Bar beneath


the clustering indicates genotype (WT: white, KO: red) (n = 3 each genotype for liver, n = 3 WT, n = 2 KO for muscle) (b). Volcano plots of the same organs as in (b) ProteinGroups only found in one condition are indicated in black (c) (n = 3 each genotype for liver, n = 3 WT, n = 2 KO for muscle).



Extended Data Fig. 2 | See next page for caption.


**Extended Data Fig. 2 | Proteome analysis of liver, muscle, and hypothalamus of neuronal inceptor KO vs. WT mice.** Principle component analysis (PCA) of all tissue samples (a). Clustering of quadriceps muscle (left) and liver (right) samples as well as z-scored protein intensities. Bar beneath the clustering

indicates genotype (WT: white, KO: red) (n = 3 each genotype) (b). Volcano plots of the same organs as in (b) ProteinGroups only found in one condition are indicated in black (c) (n = 3 each genotype).



**Extended Data Fig. 3 | AgRP or POMC neurons do not mediate neuronal effects of inceptor on glucose homeostasis.** Inceptor immunoreactivity in the hypothalamus of 20 week old C57BL/6J *Agrp-Cre<sup>+/+</sup>-Iir<sup>wt/wt</sup>* (WT) and *Agrp-Cre<sup>+/+</sup>-Iir<sup>flx/flx</sup>* mice (KO). Scale bar is 100  $\mu$ m (**a**). **b-e**, Body weight (**b**), as well as lean (**c**) and fat (**d**) tissue mass and fasting glucose (**e**) in 30 week old C57BL/6J WT and KO mice ( $n = 9$  WT,  $n = 10$  KO). **f,g**, Intraperitoneal glucose tolerance (**f**) and area under the curve (AUC) (**g**) in 30 week old male C57BL/6J WT and KO mice on a HFD ( $n = 8$  WT,  $n = 9$  KO). **h,i**, Intraperitoneal insulin tolerance (**h**) and AUC (**i**) in 31 week old male mice on a HFD ( $n = 8$  WT,  $n = 9$  KO). **j**, Inceptor immunoreactivity in the hypothalamus of 20 week old C57BL/6J *Pomc-Cre<sup>+/+</sup>-Iir<sup>wt/wt</sup>* (WT) and *Pomc-Cre<sup>+/+</sup>-Iir<sup>flx/flx</sup>* (KO) mice. Scale bar is 50  $\mu$ m. **k-n**, Body weight (**k**), as well as lean

(**l**) and fat (**m**) tissue mass and fasting glucose (**n**) in 30 week old male C57BL/6J WT and KO mice on a HFD ( $n = 9$  each genotype). **o,p**, Intraperitoneal glucose tolerance (**o**) and area under the curve (AUC) (**p**) in 30 week old male C57BL/6J WT and KO mice on a HFD ( $n = 9$  each genotype). **q,r**, Intraperitoneal insulin tolerance (**q**) and area under the curve (AUC) (**r**) in 31 week old C57BL/6J WT and KO mice ( $n = 9$  each genotype). Asterisks indicate  $**p < 0.01$ . Data present mean  $\pm$  SEM. Data in panel C, E, G, I, L, M, N, P, R were analyzed by students two-sided, two-tailed test. Data in panel D were analyzed using the Mann-Whitney Test. Data in panel B, F, H, K, O, Q were analyzed by two-way ANOVA with Bonferroni post-hoc comparison for individual time points. P-value for group differences is  $p < 0.00377$  (**E**). Corr., corrected.



Extended Data Fig. 4 | See next page for caption.



**Extended Data Fig. 4 | Proteome analysis of liver and muscle of adult-onset  $\beta$ -cell-specific inceptor KO vs. WT mice.** Principle component analysis (PCA) of all tissue samples (**a**). Clustering of quadriceps muscle (left) and liver (right) samples as well as z-scored protein intensities. Bar beneath the clustering

indicates genotype (WT: white, KO: red) (n = 4 KO, n = 5 WT for muscle, n = 5 each genotype for liver) (**b**). Volcano plots of the same organs as in (**b**) ProteinGroups only found in one condition are indicated in black (**c**) (n = 5 each genotype).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated  |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** Images were obtained as serial Z-stacks using a Leica SP5. Stained slides were digitized with an AxioScan 7 digital slide scanner. Western Blots were imaged on a Biorad Chemidoc analyser.

**Data analysis** Statistical analyses were performed using GraphPad Prism version 9. Histological analysis were performed using Visiopharm (v. 2018.9). Western Blot Densitometry analysis was performed using Biorad ImageLab 6.0.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data used for the statistical analysis are available in the data source file, along with the GraphPad Prism-derived report on the statistical analysis as appropriate. The statistical report contains the mean difference between the treatment groups, the 95% confidence intervals, the significance summary, and the exact P values (unless  $P < 0.0001$ ). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE31 partner repository with the

dataset identifier PXD046256. Raw images are included in the data source files, with exception of the histology pictures in Figure 1M,N, Figure 2M,N, and Figure 4L,M, which were too large for public repositories and are available from the corresponding author upon request.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	For animal studies, sample sizes were calculated based on a power analysis assuming that a greater or equal ( $\geq$ ) 5 g difference in body weight between genotypes can be assessed with a power of $\geq$ 75% when using a 2-sided statistical test under the assumption of a standard deviation of 3.5 and an alpha level of 0.05.
Data exclusions	No data were excluded from the analysis unless scientific (e.g. significant outlier identified by the Grubbs test for outlier) or animal welfare reasons (e.g. injury due to fighting) demanded exclusion. Outliers are stated in the data source file.
Replication	In vivo and ex vivo data were obtained in independent biological replicates as indicated in the figure legends.
Randomization	Animals were either randomly assigned into treatment groups, or were grouped based on their genotype (WT or KO). At study start, only age-matched mice were included in the studies. There were no other covariats controlled.
Blinding	For in vivo studies, drugs were aliquoted by a lead scientist in number-coded vials and most, but not all, handling investigators were blinded to the treatment condition. Analyses of glucose and insulin tolerance were performed by experienced research assistants which did not know prior treatment conditions. Ex vivo studies were performed in ID coded vials without statement of treatment on the vials. Ex vivo studies were performed in ID coded vials, and with with most, but not all investigators, being blinded to the underlying genotypes.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

rat monoclonal anti-Inceptor 2G6 produced in house by MAB core facility Helmholtz 1:200  
 rabbit anti-Pomc precursor Phoenix Pharmaceuticals, H-029-30 1:1000  
 goat anti-Agrp R&D systems, AF634 1:100  
 goat anti-GFAP Sigma, SAB2500462 1:1000  
 mouse anti-Neun, A60 Merck, MAB377 1:500  
 goat anti-Iba1 Abcam, ab107519 1:1000  
 rabbit anti-insulin Cell Signalling, #3014 1:1000  
 guinea pig anti-Glucagon Takara Bio, #M182 1:2500, 1:3000, 1:1500  
 mouse anti Akt Cell Signaling, #2920 1:1000  
 rabbit anti p-AKT S473 Cell Signaling, #4060 1:1000  
 anti-insulin Cell Signaling, #3014 1:800, 1:100  
 goat Anti-Rabbit IgG StarBright Blue 700 BioRad #12004161 1:6000  
 donkey Anti-Mouse IgG H&L (Alexa Fluor® 790) Abcam, ab175782 1:6000  
 anti-rabbit Alexa546 ; Dilution 1:2,000 Invitrogen, #A10040 1:2000  
 goat anti-guinea pig AF555 , Dilution 1:2000 Invitrogen, #A21435 1:2000  
 AlexaFluor750-conjugated goat anti-rabbit Invitrogen, #A21039 1:100

## Validation

Donkey anti-Rat IgG (H+L) Alexa Fluor™ Plus 488 Thermo Fisher, A48269 1:800  
 Donkey anti-Rat IgG (H+L) Alexa Fluor™ 568 Thermo Fisher, A78946 1:800  
 Donkey anti-Goat IgG (H+L) Alexa Fluor™ Plus 488 Thermo Fisher, A32814 1:800  
 Donkey anti-Goat IgG (H+L) Alexa Fluor™ Plus 568 Thermo Fisher, A11057 1:800  
 Donkey anti-Goat IgG (H+L) Alexa Fluor™ 647 Thermo Fisher, A21447 1:800  
 Donkey anti-Rabbit IgG (H+L) Alexa Fluor™ 488 Thermo Fisher, A21206 1:800  
 Donkey anti-Mouse IgG (H+L) Alexa Fluor™ 647 Thermo Fisher, A31571 1:800  
 Donkey anti-Rat IgG (H+L) Alexa Fluor™ 488 Thermo Fisher, A21208 1:800  
 Donkey anti-Rat IgG (H+L) Alexa Fluor™ Plus 555 Thermo Fisher, A48270 1:800

Monoclonal anti-inceptor 2G6 (produced in house by MAB core facility Helmholtz, 1:200) was validated according to Ansarullah et al. 2021, against WT and KO C57BL/6 mice on Western Blot and immunohistochemistry applications.

Rabbit anti-Pomc precursor (Phoenix Pharmaceuticals, 1:1000) is a validated polyclonal antibody used in 21 publications. Applications include Immunohistochemistry and Western Blot. The antibody reacts with POMC from mouse and rat. Based on the manufacturer, the antibody was validated on mouse and rat brain slices.

Goat anti-Agrp (R&D systems, AF634, 1:100) is a validated polyclonal antibody used in 181 publications with human samples, and 11604 publications with mouse samples. It is affinity purified, detects mouse Agrp in direct ELISAs and is recommended for immunohistochemistry.

Goat anti-GFAP (Sigma, SAB2500462, 1:1000) is a validated polyclonal antibody used in 18 publications. Goat polyclonal anti-GFAP antibody reacts with rat, canine, human, and mouse glial fibrillary acidic proteins. It is recommended for detection and quantitation of GFAP by Western blotting and immunohistochemical (IHC) techniques.

Mouse anti-Neun (Merck, MAB377, 1:500) Anti-NeuN Antibody, clone A60 detects level of NeuN and has been published and validated for use in FC, IC, IF, IH, IH(P), IP and WB. It has been used in over 5000 publications. MILLIPORE's exclusive monoclonal antibody to vertebrate neuron-specific nuclear protein called NeuN (or Neuronal Nuclei) reacts with most neuronal cell types throughout the nervous system of mice including cerebellum, cerebral cortex, hippocampus, thalamus, spinal cord and neurons in the peripheral nervous system including dorsal root ganglia, sympathetic chain ganglia and enteric ganglia. Developmentally, immunoreactivity is first observed shortly after neurons have become postmitotic, no staining has been observed in proliferative zones. The immunohistochemical staining is primarily localized in the nucleus of the neurons with lighter staining in the cytoplasm. The few cell types not reactive with MAB377 include Purkinje, mitral and photoreceptor cells. The antibody is an excellent marker for neurons in primary cultures and in retinoic acid-stimulated P19 cells. It is also useful for identifying neurons in transplants.

Goat anti-Iba1 (Abcam ab107519, 1:1000) is a validated polyclonal antibody used in 137 publications. It is affinity purified and detects rat Iba1 in liver, kidney and brain sections. It is recommended for IHC applications.

Rabbit anti Insulin (C27C9) Rabbit mAb #3014 (Cell Signaling, 1:300) is a validated monoclonal antibody used in 119 publications. Applications include Immunohistochemistry, ChIP, and Immunoprecipitation. The antibody reacts with Insulin from human, mouse and rat. Based on the manufacturer, the antibody meets all of the quality control standards defined by Cell Signaling Technology, Inc. Validations include Immunohistochemical analysis of paraffin-embedded human pancreas, showing the staining of  $\beta$  cells, using Insulin (C27C9) Rabbit mAb. The antibody is further reported to show very clear staining at 1:2000 with no background staining in primary human cells.

Anti-glucagon (Takara, M182) is a polyclonal guinea pig antibody, supplied by Takara Bio, cited in 24 publications. Applications used include IHC and CLARITY. Its a Guinea Pig polyclonal antibody raised against the peptide [HSQGTFTSDYSKYLDSRRAQDFVQWLMNT] of human Glucagon conjugated with KLH as an immunogen. The lyophilized antibody was dissolved in 50  $\mu$ l of specified water. The antibody dilutions were applied for ELISA assay by colorimetric detection using a microtiter plate immobilized with human Glucagon peptide. The expected antibody titration was obtained. Manufacturing Control: Purification: Guinea Pig serum IgG was purified by affinity column chromatography, dissolved in 10 mM PBS, pH 7.4, containing 1.0% bovine serum albumin, and then lyophilized.

Mouse anti Akt (Cell Signaling #2920, 1:1000) Akt (pan) (40D4) Mouse mAb #2920 is a validated monoclonal antibody with 1376 publications. It reacts with mouse, human, rat and monkey tissues. It is affinity purified and suitable for Western Blot, immunohistochemistry, IP.

Rabbit anti p-AKT S473 (Cell Signaling #4060, 1:1000), Phospho-Akt (Ser473) (D9E) is a validated monoclonal antibody used in 10015 publications. Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb detects endogenous levels of Akt1 only when phosphorylated at Ser473. This antibody also recognizes Akt2 and Akt3 when phosphorylated at the corresponding residues. Species Reactivity: Human, Mouse, Rat, Hamster, Monkey, D. melanogaster, Zebrafish, Bovine. It is affinity purified and suitable for Western Blot, immunohistochemistry, IP.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

### Laboratory animals

Only male mice were used in the studies, since female mice are largely resistant to diet-induced obesity and to alterations in glucose metabolism when chronically fed with a high-fat diet.

Figure 1A: 9-10-wk old male C57BL/6J wt inceptor lir +/- (WT) and inceptor lir -/- (KO) mice  
 Figure 1B: 28-wk old male C57BL/6J wt inceptor lir +/- (WT) and inceptor lir -/- (KO) mice  
 Figure 1C: 10-30-wk old male C57BL/6J wt inceptor lir +/- (WT) and inceptor lir -/- (KO) mice  
 Figure 1D and E: 19-wk old male C57BL/6J wt inceptor lir +/- (WT) and inceptor lir -/- (KO) mice

Figure 1F and G: 23-wk old male C57BL/6J wt inceptor lir +/+ (WT) and inceptor lir -/- (KO) mice  
 Figure 1H, O and P: 19-wk old male C57BL/6J wt inceptor lir +/+ (WT) and inceptor lir -/- (KO) mice  
 Figure 1I and 1J: 27-wk old male C57BL/6J wt inceptor lir +/+ (WT) and inceptor lir -/- (KO) mice  
 Figure 1K-N: 30-wk old male C57BL/6J wt inceptor lir +/+ (WT) and inceptor lir -/- (KO) mice  
 Figure 2A and B: 18-24 week old male C57BL/6J WT mice  
 Figure 2 C and D: 28 week old male C57BL/6J WT mice  
 Figure 2E: 10 week old male C57BL/6J WT mice  
 Figure 2F: 14 week old male C57BL/6J WT mice  
 Figure 3A: 11 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3B: 8-30 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3 C-F: 26 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3G and H: 27 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3 I and J: 28 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3 K: 27 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3L: 32 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 3 M and N: 36 week old male C57BL/6J Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Figure 4A: 26 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT-/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4B: 24-40 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4C-E: 30 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4 F and G: 18 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4 H and I: 18 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4 J and K: 22 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4 L and M: 26 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Figure 4 N: 18 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice  
 Extended Data Figure 1 A-C: 30 week old male C57BL/6J inceptor lir +/+ (WT) and lir -/- (KO) mice  
 Extended Data Figure 2 A-C: 36 week old male C57BL/6J inceptor Nestin Cre+/- lirwt/wt (WT) and Nestin Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3A: 20 week old male C57BL/6J Agrp-Cre+/- lirwt/wt (WT) and Agrp-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3B-G: 30 week old male C57BL/6J Agrp-Cre+/- lirwt/wt (WT) and Agrp-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3 H and I: 31 week old male C57BL/6J Agrp-Cre+/- lirwt/wt (WT) and Agrp-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3J: 20 week old male C57BL/6J Pomc-Cre+/- lirwt/wt (WT) and Pomc-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3L-P: 30 week old male C57BL/6J Pomc-Cre+/- lirwt/wt (WT) and Pomc-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 3 Q and R: 30 week old male C57BL/6J Pomc-Cre+/- lirwt/wt (WT) and Pomc-Cre+/- lirflx/flx (KO) mice  
 Extended Data Figure 4 A-C: 26 week old male Ins1 CreERT-/- lirflx/flx (WT) and Ins1 CreERT+/- lirflx/flx (KO) C57BL/6J mice

## Wild animals

no wild animals were used in the study

## Field-collected samples

no field collected animals were used in the study

## Ethics oversight

Experiments were performed in accordance with the Animal Protection Law of the European Union after permission by the Government of Upper Bavaria (Regierung von Oberbayern), Germany

Note that full information on the approval of the study protocol must also be provided in the manuscript.